Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac, T., Hickey, E.R., Ginn, J., Kashem, M., Kerr, S., Kugler, S., Li, X., Olague, A., Schlyer, S., Young, E.R.(2010) Bioorg Med Chem Lett 20: 3746-3749
- PubMed: 20471253 
- DOI: https://doi.org/10.1016/j.bmcl.2010.04.069
- Primary Citation of Related Structures:  
3NDM - PubMed Abstract: 
The discovery and SAR of a series of beta-aryl substituted pyrrolidine 2H-isoquinolin-1-one inhibitors of Rho-kinase (ROCK) derived from 2 is herein described. SAR studies have shown that aryl groups in the beta-position are optimal for potency. Our efforts focused on improving the ROCK potency of this isoquinolone class of inhibitors which led to the identification of pyrrolidine 32 which demonstrated a 10-fold improvement in aortic ring (AR) potency over 2.
Organizational Affiliation: 
Department of Medicinal Chemistry, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368, USA. todd.bosanac@boehringer-ingelheim.com